Clinical trial

Phase I Trial of PACE for Metastatic Prostate Cancer

NCT03110588

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-05-09

PhasePHASE1

Study timeline

Study start (actual)2018-05-09Date precision: day

Registry last updated2020-10-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Prostate Cancerunresolved

Interventions

PACE with Cabazitaxel (15 mg/m2)DRUG

PACE with Cabazitaxel (20 mg/m2)DRUG

Sponsors & collaborators

University of Alabama at Birminghamlead sponsor

Astellas Pharma Inccollaborator

Sanoficollaborator

Mapped research locations

BirminghamAlabama, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03110588 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.